P/42-60

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Fabrizio Samaritani, et al.

08/737,633 Serial No.:

Filed: November 15, 1996 Date: February 27

Group Art Unit

1812

For:

IFN-BETA LIQUID FORMULATIONS

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

> NOTICE OF APPEAL FROM THE PRIMARY EXAMINER TO THE BOARD OF PATENT APPEALS AND INTERFERENCES

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the decision dated October 28, 1997 of the Primary Examiner finally rejecting claims 1-10.

The Appeal Fee (\$310 - Non-Small Entity; \$155 - Small Entity) is

[XX] Enclosed

] Not required (fee paid in prior appeal)

] Charge to Deposit Account No. 15-0700

] Oral Hearing Requested and the fee therefor (\$270

Non-Small Entity; \$135 Small Entity) is enclosed.

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700. the event that the actual Appeal Fee is greater than the payment submitted herewith or is not enclosed, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on February 27, 1998

Edward A. Meilman

Name of applicant, assignee or Registered Representative

Signature

February 27, 1998 Date of Signature

EAM:ecs/mzl

Respectfully submitted,

Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN

1180 Avenue of the Americas 10036-8403 New York, New York

Telephone: (212) 382-0700 LLP